期刊文献+

Ⅱ型糖尿病脂肪肝易患因素分析 被引量:2

Relationship between incidence of fatty liver and diet and life-style in type 2 diabetes mellitus
下载PDF
导出
摘要 目的评价2型糖尿病合并脂肪肝与无脂肪肝患者饮食习惯与生活方式的差异。方法本研究涉及2型糖尿病患者370例,其中伴有脂肪肝者177例(病例组),无脂肪肝者193例(对照组)。调查两组患者饮食习惯和生活方式。结果 370例2型糖尿病患者中脂肪肝患病率为47.8%。病例组外餐、进食肥肉、油炸食品、加夜餐、饮酒以及长时间看电视的比例明显高于对照组。而病例组进食绿色蔬菜和经常锻炼的比例明显低于对照组。结论 2型糖尿病合并脂肪肝患者不良的饮食习惯和少动多坐的生活方式比糖尿病非脂肪肝组患者显著增加,提示脂肪肝的发生与生活方式和饮食习惯密切相关。 Objective To analyze the relationship between incidence of fatty liver and diet and life-style in type 2 diabetes mellitus(T2DM).Methods We enrolled 370 T2DM including 177 cases with fatty liver(Research Group) and 193 cases without fatty liver(Control group).Diet and life-style of the patients were investigated.Results The rate of fatty liver among T2DM patients was 47.8%.The incidence of fatty liver in T2DM with diet and life-styles including often dining in restaurant,oiliness food,fry,dining in night,drinking and watching TV overrun 3 hours was higher than that with out them.Conclusion The study indicates that there is obvious relationship between diet,lifestyle and fatty liver in T2DM.
出处 《西部医学》 2010年第11期2118-2119,2122,共3页 Medical Journal of West China
关键词 2型糖尿病 脂肪肝 饮食习惯 fype 2 diabetes Diet and Life-style
  • 相关文献

参考文献8

二级参考文献14

  • 1McCullough,AJ.Update on non-alcoholic fatty liver disease.J Clin Gastroenterol,2002,34:225- 262. 被引量:1
  • 2Bernal-Reyes R,Saenz-Labra A,Bernaydo-Escudero R.Prevalence of non-alcoholic steatohepatitis.Comparative study with diabetic patients. Review Gastroenterol Mexico,2000, 65: 58-62. 被引量:1
  • 3Luyckx FH,Lefebvre PJ,Scheen AJ,et al. Non-alcoholic steatohepatitis: association with obesity and insulin resistance, and influence of weight loss. Diabetes Meteb, 2000, 26:98-106. 被引量:1
  • 4Kaplan LM. Leptin,obesity,and liver disease.Gastroenterology, 1998, 115:997-1001. 被引量:1
  • 5Montague CT, Farooqi IS,Whitehead JP, et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature,1997,387:903-908. 被引量:1
  • 6Groop LC.Insulin resistance:the fundamental trigger of type 2 diabetes.Diadetes Obes Metab 1999; 1Suppl1:S1-7 被引量:3
  • 7Ginsberg HN,Huang LS.The insulin resistance syndrome:impact on lipoprotein metabolism and atherothrombosis.J Cardiovasc Risk 2000; 7(5):325-31 被引量:1
  • 8Beek-Nielsen H,Groop LC.Metabolic and genetical characterization Of prediabetic states.J Clin Invest 1994; 94:1714-21 被引量:1
  • 9Bonora E,Targher G,Zenere MB,et al.Relationship between fasting insulin cardiovascular risk factors is already present in young men:the Verona Yong Men Atherosclerosis Risk Factors Study.Eur J Clin Invest 1999; 27:248-54 被引量:1
  • 10Shanthirani CS,Pradeepa R,Deepa R,et al.Prevalence and risk factors of hypertension in a selected South Indian population-the Chennai Urban Population Study.J Assoc Physicians India 2003; 51:20-7 被引量:1

共引文献76

同被引文献22

  • 1高伟,任瑞珍,唐与晓,王秋灵,王玮,孟晓梅.2型糖尿病脂肪肝的筛查及相关因素分析[J].中华糖尿病杂志(1006-6187),2005,13(2):105-107. 被引量:42
  • 2International Diabetes Federation. IDF Diabetes Atlas[M]. 6th Edition. Brussels: Znternatinal Diabetes Febration, 2013. 被引量:1
  • 3Balaban YH, Korkusuz P, Simsek H, et al. Dipeptidy[peptidase IV(DPP IV) in NASH patients [J]. Ann Hepatol, 2007,6 (4) : 242-250. 被引量:1
  • 4Yilmaz Y,Atug O,Yonal O,etal. Dipeptidyl peptidase IV inhibi- tors: therapeutic potential in nonalcoholic fatty liver disease [J]. Med Sci Monit,2009,15(4) : HY1-5. 被引量:1
  • 5Itou M, Kawaguchi T, Taniguchi E, et al. Dipeptidyl peptidase IV inhibitor improves insulin resistance and steatosis in a refrac- tory nonalcoholic fatty liver disease patient: a case report [J]. Gastroenterology, 2012,6 (2) : 538-544. 被引量:1
  • 6Neuschwander-Tetri BA,Caldwell SH. Nonalcoholic Steatohepa- titis:summary of an AASLD single topic conference [J]. Hepa- tology,2003,37(5) : 1202-1219. 被引量:1
  • 7Gupta NA, Mells J, Dunham RM, et al. Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway [J]. Hepatology, 2010, 51 (5): 1584-1592. 被引量:1
  • 8Viollet B, Guigas B, Leclerc J, et al. AMP-activated protein ki- nase in the regulation of hepatic energy metabolism:From physi- ology to thera- peutic perspectives [ J]. Acta Physiol, 2009,196 (1) :81-98. 被引量:1
  • 9Iwasaki T, Yoneda M, Inamori M, et al. Sitagliptin as a novel treatment agent for non-alcoholic fatty liver disease patients with type 2 diabetes mellitus [J]. Hepatogastroenterology, 2011,58 (112) :2103-2210. 被引量:1
  • 10Charbonnel B,Karasik A,Liu J, et al. Efficacy and safety of the dipeptide peptidase-4 inhibitor sitagliptin added to ongoing met- formin therapy in patients with type 2 diabetes inadequately con- trolledwith metformin alone [J]. Diabetes Care, 2006,29 (12) : 2638-2643. 被引量:1

引证文献2

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部